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RESEARCH ARTICLE
Secondary consent to biospecimen use 
in a prostate cancer biorepository
Bettina F. Drake1,2* , Katherine Brown1, Lucy D’Agostino McGowan3, Jennifer Haslag‑Minoff4 
and Kimberly Kaphingst5,6
Abstract 
Background: Biorepository research has substantial societal benefits. This is one of the few studies to focus on male 
willingness to allow future research use of biospecimens.
Methods: This study analyzed the future research consent questions from a prostate cancer biorepository study 
(N = 1931). The consent form asked two questions regarding use of samples in future studies (1) without and (2) 
with protected health information (PHI). Yes to both questions of use of samples was categorized as Yes‑Always; Yes 
to without and No to with PHI was categorized as Yes‑Conditional; No to without PHI was categorized as Never. We 
analyzed this outcome to determine significant predictors for consent to Yes‑Always vs. Yes‑Conditional.
Results: 99.33 % consented to future use of samples; 88.19 % consented to future use without PHI, and among those 
men 10.2 % consented to future use with PHI. Comparing Yes Always and Yes Conditional responses, bivariate analy‑
ses showed that race, family history, stage of cancer, and grade of cancer (Gleason), were significant at the α = 0.05 
level. Using stepwise multivariable logistic regression, we found that African–American men were significantly more 
likely to respond Yes Always when compared to White men (p < 0.001). Those with a family history of prostate cancer 
were significantly more likely to respond Yes Always (p = 0.002).
Conclusions: There is general willingness to consent to future use of specimens without PHI among men.
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Background
Research with stored biospecimens has generated exten-
sive clinical data essential for the advancement of transla-
tional medicine [1–7]. Such research can provide critical 
societal benefits, including enhanced medical treatments 
and improved national health outcomes [5, 6, 8]. How-
ever, the question of patient donation of biospecimens for 
unplanned secondary research purposes raises important 
ethical considerations [4–7]. Biospecimen donors who 
consent to unspecified future research uses are vulnera-
ble to protected health information (PHI) disclosure, loss 
of control, and risk of exploitation [3–7]. However, regu-
lations require researchers to be diligent in the security 
and safety of all data, specifically, PHI on participants. 
Under the Health Insurance Portability and Accountabil-
ity Act (HIPAA) PHI includes social security and medical 
record numbers, names, zip codes, dates of birth, contact 
information including telephone, fax, email and mailing 
addresses. The views and willingness of participants to 
provide PHI along with samples and health information 
is important to fully explore. The Department of Health 
and Human Services is currently revising the ‘Common 
Rule’ to require a broad informed consent for secondary 
research with a biospecimen even if PHI is not being pro-
vided [9]. Research on individuals’ attitudes and willing-
ness to donate biospecimens for unplanned future uses 
are essential for informing these ethical concerns [4–7]. 
It is important to further recognize the lack of informa-
tion surrounding biorepository participation and patient 
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These issues are particularly salient in the context of 
cancer. Research with stored biospecimens can provide 
a greater understanding of cancer etiology and discov-
ery of new therapeutic modalities [4–7]. Participation in 
biobanks by large numbers of diverse participants is criti-
cal to reaching translational research goals in cancer and 
reducing cancer disparities [8]. However, participants who 
donate biospecimens for research may face risks related 
to unwanted disclosure of PHI which may affect willing-
ness to participate among diverse individuals [10, 11]. A 
disproportionate burden of cancer disparities is borne by 
communities increasingly of interest to biobank research-
ers but few studies have examined the consent preferences 
and needs of underserved communities [12, 13].
In order to gain further insight into these attitudes 
towards secondary biospecimen usage, research must 
include underrepresented minorities and groups [3, 6, 
8, 14]. One group that has been particularly underrepre-
sented in this type of research is males, specifically Afri-
can American men. The proposed study responds to this 
gap in the literature by including African American male 
prostate cancer patients and investigating their willing-




This study analyzed secondary questions added to a con-
sent form regarding consent for future research uses of 
biospecimens. The primary consent was for participa-
tion in a prostate cancer biorepository study (N = 1931) 
among White and African American (12.3 %) men. The 
prostate cancer biorepository study enrolled men after 
a prostate cancer diagnosis but before treatment to col-
lect serum and tissue for analyses on genetic, dietary and 
clinical risk factors for prostate cancer recurrence and 
mortality. Participants consented to participate in a study 
that will assess genetic risk for prostate cancer outcomes. 
At enrollment, a detailed chart review is performed to 
document the patient’s medical history as well as the 
clinical characteristics of their cancer diagnosis and 
treatment. The Washington University in St. Louis Insti-
tutional Review Board approved this study and consent 
procedures.
Variable definition
On the consent form, men were asked three separate 
questions regarding participation in future studies: (1) 
May we use the materials collected in this study to ana-
lyze other factors? Other factors may include analyses, 
other than genetic, of markers derived from stored serum 
which were not part of the original research question. (2) 
May we share your information with other investigators 
at our institution without any PHI? (3) May we share 
your information with other investigators at our insti-
tution with PHI? All men were asked questions 1 and 
2. Only men who responded yes to question 2 (May we 
share your information with other investigators at our 
institution without any PHI?) were asked question 3 
regarding use of information with PHI. If a participant 
responded No to question 2 (use without PHI), they were 
not asked question 3 (use with PHI) (see Fig.  1). Men 
who responded Yes to question 2 (use without PHI) and 
Yes to question 3 (use with PHI) were categorized as Yes 
Always consent for future use. Men who responded Yes 
to question 2 (use without PHI) and No to question 3 
(use with PHI) were categorized as Yes Conditional con-
sent for future use. Men who responded No to question 2 
(use without PHI) were categorized as Never consent for 
future use.
Predictors of consent for future use were obtained from 
the baseline survey and clinical data obtained from par-
ticipants in the cohort at the time of diagnosis. Variables 
assessed were race, age, marital status, employment sta-
tus, smoking history, family history of prostate cancer, 
stage of cancer, and grade of cancer.
Statistical analysis
Statistical analyses were performed by using SAS/STAT® 
9.4 (SAS Institute, Cary, NC). Because so few patients 
were in the “Never” group, we limited the bivariate and 
multivariate analyses to only participants in the “Yes 
Always” and “Yes Conditional” groups. Since very few 
participants were in the “Other” race category, we lim-
ited the analysis to African American/Black and White 
participants. We performed bivariate analyses using Chi 
squared tests for categorical variables (race, marital sta-
tus, employment status, smoking history, family history 
of prostate cancer, stage of cancer, and grade of cancer) or 
Fisher’s exact test for variables with expected cell counts 
less than 5 and a student’s t test for the continuous vari-
able, age. Multivariable logistic regression analyses were 
used to identify factors associated with consent for future 
use responses. In these models, age was continuous, and 
the remaining variables, race, marital status, employment 
status, smoking history, family history of prostate can-
cer, stage of cancer, and grade of cancer (Gleason), were 
categorical. We employed stepwise selection with entry 
criteria set at 0.1 and the cutoff of 0.05 to remain in the 
model. Participants were excluded if they had missing 
data for any of the variables included in the model.
Results
There were 1931 participants who responded to the sec-
ondary consent questions. 99 % consented to future use 
for other factors; 88 % consented to future use with other 
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investigators without any PHI, and among those men 
10.2  % consented to future use with other investigators 
with PHI. Descriptive statistics of the participants are 
reported in Table 1.
Figure 2 displays the percent of consent for future use 
option stratified by family history of prostate cancer. This 
chart shows that 13 % of those who responded “Yes” to 
having a family history of prostate cancer responded “Yes 
Always” as compared to 8  % of those who responded 
“No” to having a family history of prostate cancer. 
Figure  3 displays the percent of consent for future use 
option stratified by race. From this chart, we can see that 
23 % of African American/Black participants responded 
“Yes Always”, as compared to 8 % of White participants 
that responded the same.
Of the 1931 participants, 1900 responded “Yes Always” 
or “Yes Conditional” to consent to future use. Due to the 
small number of participants that responded “Never” 
(N = 31) and the small number of participants who indi-
cated that they identified as a race other than African 
American/Black or White (N  =  12), we excluded these 
participants from the remainder of our analyses, leav-
ing 1889 participants. Table  2 shows the prevalence of 
response type by age, race, marital status, employment 
status, smoking history, family history of prostate cancer, 
stage of cancer, and grade of cancer. The variables race, 
family history, stage of cancer, and grade of cancer were 
significantly associated with consent for future use when 
analyzed alone. Black participants were 3.49 times more 
likely to agree to consent for future use “Always” when 
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Fig. 1 Consent for future use definition
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compared to the White participants (p  <  0.001). Those 
with a family history of prostate cancer were 1.69 times 
more likely to agree to consent to future use “Always” 
when compared to those without a family history 
(p = 0.001). Prostate cancer is defined as clinical stage 1 
if it is detected by PSA screening only and is not detect-
able by imaging. As noted in Table  1, most men in our 
sample are classified as Clinical Stage T1c, meaning their 
prostate cancer was identified by needle biopsy. Prostate 
cancer is defined as clinical tumor stage T2 if there is a 
tumor present, and it is confined within the prostate [15]. 
Participants with clinical tumor stage T2 cancer were 
less likely to agree to consent to future use “Always” com-
pared to men with clinical tumor stage T1 cancer (OR: 
0.52, p  =  0.005). However, men with a Gleason score 
of 7 were 1.93 times more likely to agree to consent to 
future use “Always” than men with lower Gleason scores 
(p < 0.001).
In a combined model, race and family history of pros-
tate cancer were significant with an alpha  =  0.1 cri-
teria for entry into the model and alpha =  0.05 criteria 
to remain in the model. There were 1694 participants 
included in our final model. Of these, 1522 (89.8  %) 
responded “Conditional” to consent to future use, and 
172 (10.2  %) responded “Always”. The final predic-
tion model with race and family history can be seen in 
Table 3. In this combined model, Black participants were 
Table 1 Descriptive characteristics
N n (%)
Outcomes
 Does patient agree to allow study team to 
analyze other factors?
1931
  Yes 1918 (99.33)
  No 13 (0.67)
 Consent for future use 1931
  Yes always 197 (10.2)
  Yes conditional 1703 (88.19)
  Never 31 (1.61)
Predictors
 Age at diagnosis 1859
Mean (SD) 61.03 (7.41)
 Race 1931
  White 1682 (87.11)
  Black 237 (12.27)
  Other 12 (0.62)
 Family history of prostate cancer 1733
  Yes 615 (35.49)
  No 1118 (64.51)
 Marital status 1322
  Married 1133 (85.70)
  Separated/divorced/widowed 155 (11.72)
  Never married 34 (2.57)
 Employment status 1312
  Employed 712 (54.27)
  Retired 530 (40.40)
  Unemployed 47 (3.58)
  Other 23 (1.75)
 Smoking status 1889
  Never smoked 918 (48.60)
  Former smoker 753 (39.86)
  Current smoker 218 (11.54)
 Clinical stage 1881
  T1c 1512 (80.38)
  T2a/T2b/T2c 369 (19.62)
 Gleason score 1888
  2–6 1147 (60.75)
  7 587 (31.09)
  8+ 154 (8.16)
Fig. 2 Secondary consent by family history of prostate cancer
Fig. 3 Secondary consent by race
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3.17 times more likely to agree to consent for future use 
“Always” (p < 0.001); likewise, men with a family history 
of prostate cancer were 1.67 times more likely to agree to 
consent for future use “Always” (p = 0.002).
Discussion
There is a general willingness to consent to secondary 
research use of biospecimens among men without PHI. 
While African American men are more likely to con-
sent to future research “Never” than men of other racial 
backgrounds, those who do agree are more likely to say 
“Yes Always” to research with and without PHI when 
Table 2 Bivariate associations between  sociodemographic and  clinical predictors and  willingness to  donate biospeci-
mens for future research uses (N = 1889)
* Significant at the α = 0.05 level
a t value is calculated for continuous variables





χ2 OR (95 % CI)
always (vs. conditional)
p value
Age at diagnosis 1859
 Mean (SD) 61.0 (7.4) 61.4 (7.2) −0.75a – 0.453
Race 1889 54.28 <0.001*
 White 1523 (90.0) 142 (72.1) 1.00 (ref )
 Black 169 (10.0) 55 (27.9) 3.49 (2.46, 4.95)
Family history 1694 10.53 0.001*
 No 1004 (66.0) 92 (53.5) 1.00 (ref )
 Yes 518 (34.0) 80 (46.5) 1.69 (1.23, 2.32)
Marital status 1301 0.415b
 Married 1049 (86.0) 66 (81.5) 1.00 (ref )
 Not currently married 141 (11.6) 12 (14.8) 1.35 (0.71, 2.57)
 Never married 30 (2.5) 3 (3.7) 1.59 (0.47, 5.34)
Employment status 1292 0.104b
 Employed 661 (54.6) 40 (49.4) 1.00 (ref )
 Retired 489 (40.4) 32 (39.5) 1.08 (0.67, 1.75)
 Unemployed 41 (3.4) 6 (7.1) 2.42 (0.97, 6.04)
 Other 20 (1.7) 3 (3.7) 2.48 (0.71, 8.70)
Smoking 1847 0.34 0.844
 Never smoked 800 (48.4) 98 (50.2) 1.00 (ref )
 Former smoker 660 (39.9) 75 (38.7) 0.93 (0.68, 1.28)
 Current smoker 193 (11.7) 21 (10.8) 0.89 (0.54, 1.46)
Stage 1841 7.78 0.005*
 T1c 1316 (79.4) 162 (88.0) 1.00 (ref )
 T2a/T2b/T2c 341 (20.6) 22 (12.0) 0.52 (0.33, 0.83)
Gleason score 1846 17.22 <0.001*
 2–6 1035 (62.5) 89 (47.1) 1.00 (ref )
 7 489 (29.5) 81 (42.9) 1.93 (1.40, 2.65)
 8+ 133 (8.0) 19 (10.1) 1.66 (0.98, 2.82)
Table 3 Logistic regression predicting willingness 
to  donate biospecimens for  future research uses 
(N = 1694)
Effect OR 95 % CI p value
Odds ratio estimates always (vs. conditional)
  Race <0.001
  White 1.00 (ref ) – –
  Black 3.17 2.15 4.67
 Family history 0.002
  No 1.00 (ref ) – –
  Yes 1.67 1.21 2.31
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compared to the White population. Additionally, those 
with a family history are more likely to agree to second-
ary uses with PHI than those without a family history as 
compared to agreeing to secondary use only without PHI.
Past literature has investigated the attitudes of females 
regarding initial and secondary usage of biospecimens 
[1–5, 7]. Female participation in biospecimen research 
has reflected high rates of willingness and consent for 
unlimited future research [4, 7]. Of those studies that 
included males, a number of studies have found that there 
was no significant difference between sexes when meas-
uring willingness to participate in secondary research use 
of biospecimens [1, 5, 7]. Studies that further compared 
healthy male and female volunteers to diseased individu-
als also did not find any significant difference in consent 
for future use of biospecimens [3, 7]. One past research 
study that exclusively surveyed male cancer patients 
showed 100  % consent rate to participate in biobank 
donation [6]. However, few studies have focused only on 
males. In addition, our study assessed actual donors’ con-
sent and not just willingness to consent. Past research has 
also found significant differences in consent for future 
uses of secondary biospecimens between races, particu-
larly comparing Caucasians and African Americans [1, 5, 
7]. Some studies found no significant difference in con-
sent for biospecimen studies [16, 17], while another study 
found African–Americans were less likely but with a high 
percentage of 75  % African Americans consenting to a 
biospecimen study [18]. Our study focuses on consent to 
secondary use of biospecimens and only focuses on men 
which have not been thoroughly evaluated in previous 
studies.
Despite the large percentage of men who agreed to 
future use of their biospecimens in our study, many did 
not consent to sharing their PHI in future research pro-
jects. Usability of de-identified biospecimens differs from 
those with identifiers attached. Many pathology depart-
ments have developed honest broker services which 
provide a firewall between clinical records and research 
studies. The honest broker provides de-identified clinical 
data to researchers for research use only [19]. However in 
the absence of an honest broker, participants must pro-
vide consent for secondary use of their biospecimens. 
However, data from de-identified biospecimens may still 
be analyzed and utilized by clinical investigators; several 
studies using de-identified samples have been able to 
confirm and replicate previous findings [20, 21].
This study had a few limitations. In order to participate 
in the initial study, participants had to agree to genetic 
analyses; therefore we are unable to determine if prefer-
ences for secondary genetic research would be similar to 
the preferences for secondary research with vs. without 
PHI described here. In addition, of the 31 who were cat-
egorized as consenting to future use “Never”, only 12 
responded No to the initial question, “May we use the 
materials collected in this study to analyze other factors?” 
The other 19 men agreed to allow the study team to ana-
lyze other factors but under no circumstances (with or 
without PHI). This may speak to some confusion in the 
consent process among participants when they respond 
yes or no to allow researchers to analyze other factors. 
More African American men chose the extremes of Yes 
Always or Never.
Future research should focus on informed decision 
making studies to assess whether these choices are in 
alignment with their values and preferences. In addition, 
studies are needed to examine whether more focused 
education about the protections in place for PHI would 
encourage unrestricted donation of biospecimens.
Conclusions
It is critical for researchers to understand patient percep-
tions and needs of all population subgroups in order to 
provide fair and just treatment regarding biospecimen 
collection practices and to improve informed decision 
making about biospecimen donation. Based on our find-
ings, there is general willingness to consent to future use 
of specimens without PHI among men. We found there 
were differences by race in consent to secondary use of 
biospecimens. Inclusion of underrepresented popula-
tions in biospecimen research is critically needed to 
enhance diversity within biobanks so that results gener-
ated by biobank research are applicable to all segments of 
the population. Otherwise, the societal benefits of trans-
lational research using biospecimens are limited. The 
current study is the first to investigate the willingness and 
participation extent in secondary biospecimen research 
in an underrepresented group, African American men. 
This study can inform consent protocols and educational 
needs for enrolling male patients from different popula-
tion groups into biobanks.
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